# Unicar-Therapy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unicar-therapy

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.unicar-therapy.com
- Latest round: Series B (Mar 31, 2021)
- Investors on record: 5

## About

Established in 2015 and based in Shanghai, China, Unicar-Therapy is a biotechnology company that focuses on the development of CAR-T and other cell/gene therapy technologies and products. Unicar-Therapy has won many honors, such as the China Cell Therapy Enterprise Rapid Growth Award, the 2019 Future Medical Top 100 - Top 100 China Innovative Medicine List, and the 2020 Top 100 Chinese Pharmaceutical Innovation Enterprises. Unicar-Therapy cooperated with Hainan Haiyao to build a gene and cell therapy center in Hainan.

The company is committed to the development of CAR-T and other cell/gene therapy products. It uses CAR-T therapy, builds antibody screening platforms and GMP production bases to develop CAR-T products for tumor treatment, and has completed more than 1,000 CAR-T clinical studies and treatments with the hematology departments of many domestic hospitals. In September 2020, Yucardi received approval for a new CAR-T2.0 product, SSCART-19 injection, in a formal clinical trial.

## Funding rounds

- Series B, Mar 31, 2021 — Shanghai Deguan Asset Management
- Series B, Jun 14, 2019 — Alwin Capital, Hainan Haiyao, Shanghai Deguan Asset Management
- Series A, Mar 1, 2016 — Apricot Capital, Shanghai Yuchen Investment

## Investors

- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A
- Shanghai Yuchen Investment — Series A
- Alwin Capital — Series B
- Hainan Haiyao — Series B
- Shanghai Deguan Asset Management (https://capitalatlas.ai/funds/shanghai-deguan-asset-management) — Series B